Outcome of intravesical doxorubicin installation in T1 non muscle invasive bladder cancer: experience from a tertiary hospital in Indonesia
Keywords:
NMIBC;, TURBT;, doxorubicin;, intravesical;, oncological outcome
Abstract
In Indonesia, the proportion of non-muscle bladder cancer is low compared to other countries. Doxorubicin is currently one of options for adjuvant therapy for nonmuscle invasive bladder (NMIBC) that underwent transurethral resection of bladder tumor (TURBT). This study is aimed to evaluate the oncological outcome of doxorubicin intravesical. Eight consecutive T1 bladder patients who underwent TURBT with complete tumor resection, and received intravesical chemotherapy were enrolled in this study. All the clinical data were gathered retrospectively. One of eight patients did not respond to intravesical doxorubicin instillation. Patients were recorded with univocal, low grade and female patients. In conclusion, doxorubicin intravesical may be one of options. Despite a small number of samples were enrolled. This preliminary data showed promising results on intravesical doxorubicin instillation.
References
1. Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. Jpn J Clin Oncol 2015; 45(8):708-12.
https://doi.org/10.1093/jjco/hyv066
2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306(7):737-45.
https://doi.org/10.1001/jama.2011.1142
3. Van Osch FH, Jochems SH, Van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016; 45(3):857-70.
https://doi.org/10.1093/ije/dyw044
4. Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers 2022; 14(13):3073.
https://doi.org/10.3390/cancers14133073
5. Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 2014; 5(24):12665-74.
https://doi.org/10.18632/oncotarget.2851
6. Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA, McKiernan J, et al. Best practices to optimise quality and outcomes of transurethral resection of bladder tumours. Eur Urol Oncol 2021; 4(1):12-9.
https://doi.org/10.1016/j.euo.2020.06.010
7. Abufaraj M, Mostafid H, Shariat SF, Babjuk M. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. Curr Opin Urol 2018; 28(6):570-6.
https://doi.org/10.1097/MOU.0000000000000544
8. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81(1):75-94.
https://doi.org/10.1016/j.eururo.2021.08.010
9. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 2016; 196(4):1021-9.
https://doi.org/10.1016/j.juro.2016.06.049
10. Hendri AZ, Hamid ARAH, Hakim L, Warli SM, Prasetyawan W, Danarto HR, et al. Panduan penanganan kanker kandung kemih tipe urotelial. Ikatan Ahli Urologi Indonesia (IAUI) 2014; 1-56.
11. Al-Gallab MI, Naddaf LA, Kanan MR. The management of non-invasive bladder tumours with doxorubicin intravesical instillation after transurethral resection. Sultan Qaboos Univ Med J 2009; 9(1):53-8.
12. Fukuokaya W, Kimura T, Miki J, Kimura S, Watanabe H, Bo F, et al. Effectiveness of intravesical doxorubicin immediately following resection of primary non–muscle-invasive bladder cancer: a propensity score-matched analysis. Clin Genitourin Cancer 2020; 18(2):e55-61.
https://doi.org/10.1016/j.clgc.2019.09.005
13. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163(4):1124-9.
14. Sylvester RJ, Van Der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC Risk Tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3):466-77.
https://doi.org/10.1016/j.eururo.2005.12.031
15. Gontero P, Comperat EAB, Dominguez Escrig JL, Mariappan LE, Masson-Lecomte A, Mostafid AH, et al. EAU Guidelines on non-muscle-invasive (TaT1, CIS) bladder cancer. Congress Milan 2023. ISBN 978-94-92671-19-6.
16. Reid LM, Leav I, Kwan PW, Russell P, Merk FB. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res 1984; 44(10):4560-73.
17. Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? Transl Androl Urol 2016; 5(5):668-82.
https://doi.org/10.21037/tau.2016.03.22
18. Zlotta AR, Vooren JPV, Huygen K, Drowart A, Decock M, Pirson M, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37(4):470-7.
https://doi.org/10.1159/000020170
19. Soloway MS. Overview of treatment of superficial bladder cancer. Urol 1985; 26(4 Suppl):18-26.
https://doi.org/10.1093/jjco/hyv066
2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306(7):737-45.
https://doi.org/10.1001/jama.2011.1142
3. Van Osch FH, Jochems SH, Van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016; 45(3):857-70.
https://doi.org/10.1093/ije/dyw044
4. Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers 2022; 14(13):3073.
https://doi.org/10.3390/cancers14133073
5. Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 2014; 5(24):12665-74.
https://doi.org/10.18632/oncotarget.2851
6. Mostafid H, Kamat AM, Daneshmand S, Palou J, Taylor JA, McKiernan J, et al. Best practices to optimise quality and outcomes of transurethral resection of bladder tumours. Eur Urol Oncol 2021; 4(1):12-9.
https://doi.org/10.1016/j.euo.2020.06.010
7. Abufaraj M, Mostafid H, Shariat SF, Babjuk M. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. Curr Opin Urol 2018; 28(6):570-6.
https://doi.org/10.1097/MOU.0000000000000544
8. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81(1):75-94.
https://doi.org/10.1016/j.eururo.2021.08.010
9. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 2016; 196(4):1021-9.
https://doi.org/10.1016/j.juro.2016.06.049
10. Hendri AZ, Hamid ARAH, Hakim L, Warli SM, Prasetyawan W, Danarto HR, et al. Panduan penanganan kanker kandung kemih tipe urotelial. Ikatan Ahli Urologi Indonesia (IAUI) 2014; 1-56.
11. Al-Gallab MI, Naddaf LA, Kanan MR. The management of non-invasive bladder tumours with doxorubicin intravesical instillation after transurethral resection. Sultan Qaboos Univ Med J 2009; 9(1):53-8.
12. Fukuokaya W, Kimura T, Miki J, Kimura S, Watanabe H, Bo F, et al. Effectiveness of intravesical doxorubicin immediately following resection of primary non–muscle-invasive bladder cancer: a propensity score-matched analysis. Clin Genitourin Cancer 2020; 18(2):e55-61.
https://doi.org/10.1016/j.clgc.2019.09.005
13. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus calmette-guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163(4):1124-9.
14. Sylvester RJ, Van Der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC Risk Tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3):466-77.
https://doi.org/10.1016/j.eururo.2005.12.031
15. Gontero P, Comperat EAB, Dominguez Escrig JL, Mariappan LE, Masson-Lecomte A, Mostafid AH, et al. EAU Guidelines on non-muscle-invasive (TaT1, CIS) bladder cancer. Congress Milan 2023. ISBN 978-94-92671-19-6.
16. Reid LM, Leav I, Kwan PW, Russell P, Merk FB. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res 1984; 44(10):4560-73.
17. Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? Transl Androl Urol 2016; 5(5):668-82.
https://doi.org/10.21037/tau.2016.03.22
18. Zlotta AR, Vooren JPV, Huygen K, Drowart A, Decock M, Pirson M, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37(4):470-7.
https://doi.org/10.1159/000020170
19. Soloway MS. Overview of treatment of superficial bladder cancer. Urol 1985; 26(4 Suppl):18-26.
